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Summary 
 
The genome-wide localization and function of endogenous Dnmt3a and Dnmt3b in 
adult stem cells are unknown. Here, we show that in human epidermal stem cells the 
two proteins bind in a histone H3K36me3–dependent manner to the most active 
enhancers and are required to produce their associated enhancer RNAs. Both proteins 
prefer super-enhancers associated to genes that either define the ectodermal lineage or 
establish the stem cell and differentiated states. However, Dnmt3a and Dnmt3b differ 
in their mechanisms of enhancer regulation: Dnmt3a associates with p63 to maintain 
high levels of DNA hydroxymethylation at the center of enhancers in a Tet2-
dependent manner, whereas Dnmt3b promotes DNA methylation along the body of 
the enhancer. Depletion of either protein inactivates their target enhancers and 
profoundly affects epidermal stem cell function. Altogether, we reveal novel functions 
for Dnmt3a and Dnmt3b at enhancers that could contribute to their roles in disease 
and tumorigenesis.  
 
 
 
 
 
 
 
 
 
 
  
Introduction 
Establishing cell fates during development depends on de novo DNA methylation 
catalyzed by Dnmt3a and Dnmt3b (Okano et al., 1999; Wu and Zhang, 2014). Both 
proteins also play important roles in adult tissue homeostasis (Challen et al., 2014; 
Rinaldi and Benitah, 2014; Wu et al., 2010), and their deregulation is causative of 
disease, including tumorigenesis (Timp and Feinberg, 2013). Depletion of the DNA 
methyltransferases Dnmt3a, Dnmt3b, or Dnmt1 perturbs the homeostasis of several 
tissues, including the epidermis, hematopoietic cells, lung, intestine, and neural cells 
(Broske et al., 2009; Challen et al., 2014; 2012; Sheaffer et al., 2014; Trowbridge et 
al., 2009). Naturally occurring somatic mutations in Dnmts can drive hematologic 
malignancies and are causative of a diseased state (Rinaldi and Benitah, 2014; Shaffer 
et al., 2014; Shlush et al., 2014; Sun et al., 2014). Interpreting these phenotypes has 
been hampered by the lack of information regarding the genomic localization of each 
endogenous protein in adult tissues.  
 
Here we studied the role of endogenous Dnmt3a and Dnmt3b during human 
epidermal stem cell (EpSC) differentiation. Expression of the maintenance DNA 
methyltransferase Dnmt1 is high in the basal cells of the epidermis and decreases as 
the basal cells differentiate, leading to a decrease in the content and amplitude of 
DNA methylation in differentiated keratinocytes as compared to epidermal basal cells 
(Sen et al., 2010). Dnmt1-deficient human EpSCs undergo premature and irreversible 
differentiation (Sen et al., 2010), although it is not known to what extent this effect is 
dependent on changes in DNA methylation. Intriguingly, conditional Dnmt1 deletion 
in mouse epidermis only results in uneven epidermal thickness and a reduction of the 
hair follicle length during ageing (Li et al., 2012). While genome-wide single-base 
pair resolution analysis of DNA methylation revealed similar patterns between 
quiescent and active proliferating hair follicle stem cells in young mice (Bock et al., 
2012), it also identified more than 2,000 differentially methylated regions. If and how 
de novo DNA methyltransferases regulate the function of EpSCs and their 
differentiated counterparts is unknown. We now reveal that Dnmt3a and Dnmt3b have 
previously unidentified functions through their association with distal transcriptional 
regulatory elements during EpSC homeostasis.  
 
Results 
Dnmt3a and Dnmt3b are Differentially Expressed During Human EpSC 
Differentiation 
To study the dynamics of EpSC differentiation, we have previously monitored the 
stepwise changes in gene expression during differentiation every five hours for two 
consecutive days (Janich et al., 2013; Luis et al., 2011; Sen et al., 2010). Expression 
of stem cells and differentiation markers followed the expected pattern during 
differentiation (Toufighi et al., 2015).  The de novo DNA methyltransferases Dnmt3a 
and Dnmt3b were highly expressed in EpSCs, but Dnmt3a increased during 
differentiation, while Dnmt3b diminished at the onset of differentiation (Figure S1A–
B and Table S1A).  
 
Dnmt3a and Dnmt3b Dynamically Bind to the Most Active Enhancers During 
EpSC Differentiation 
To study whether expression changes in the de novo DNA methyltransferases during 
EpSC differentiation are functionally relevant, we performed ChIP-seq of both 
endogenous proteins in two biological replicates (Figures 1 and S1C). The Pearson 
correlation coefficients for the biological replicates were 0.72 and 0.89 for Dnmt3a 
and Dnmt3b, respectively (Table S2A). Using DeSeq2 as a stringent statistical 
method to measure differential binding, we observed that Dnmt3a occupied more 
sites, and Dnmt3b fewer sites, during stem cell differentiation, mirroring their 
expression pattern during differentiation (Figure S1C and Table S2B). MACS-peak 
calling revealed that, of the peaks common between stem cells and differentiated 
states, 68% of Dnmt3a peaks significantly increased in amplitude during 
differentiation, while 75% of Dnmt3b peaks decreased (Figure S1D). Thus, genomic 
sites occupied by Dnmt3a increase, and those occupied by Dnmt3b decrease, during 
human EpSC differentiation.   
 
Genomic localization of the two proteins showed little overlap, suggesting they have 
specific and dynamic functions (Table S2B). To better map these distinct genomic 
locations, we performed ChIP-seq in stem cells and differentiated cells for H3K4me3 
(for active promoters), H3K4me1 (for enhancers), H3K27ac (for active enhancers and 
transcribed genes), methylated DNA (using MeDIP and whole genome bisulfite 
sequencing), and hydroxymethylated DNA (hMeDIP) (Figure S1F and Table S3A). 
We also analyzed both cell states with RNA-seq to correlate the genomic localization 
of Dnmt3a and Dnmt3b with changes in their gene expression (Figure S1E). 
 
A significant proportion of the genomically-bound Dnmt3a and Dnmt3b was located 
at intergenic regions (Figures 1A–D and Table S2B). These sites are rich in H3K4me1 
and H3K27ac, which define enhancers (Figure 1A). Enhancers promote distal gene 
expression by physically connecting with their promoters. Dynamic changes in 
enhancer activity regulate the expression of cell fate genes during development (Hon 
et al., 2013; Smith and Shilatifard, 2014). They can be either poised (H3K4me1-
positive) or active (H3K4me1/H3K27ac–double positive) and produce bidirectional 
enhancer RNAs (eRNAs) that stabilize the interactive loop with promoters (Kim and 
Shiekhattar, 2015; Lai and Shiekhattar, 2014). We first analyzed enhancer behavior 
during human EpSC differentiation with ChIP-seq analysis of H3K4me1 and 
H3K27ac in three biological triplicates of EpSCs and their differentiated counterparts 
(Figure S1G). DeSeq2 showed that the majority (76%) of active enhancers in human 
EpSCs are significantly decommissioned during differentiation (Figure S1H and 
Table S3B). Strikingly, 11,825 enhancers were enriched exclusively in the stem cell 
state; proximity analysis suggested that these enhancers drove the expression of genes 
that define the ectoderm lineage—and therefore functionality—of stem cells, such as 
ITGA6, TP63, KRT5, and KRT14 (Figure S1H). Upon terminal differentiation, 110 
enhancers were activated de novo; those enhancers are associated to epidermal 
differentiation genes such as involucrin, cornifin, and other members of Epidermal 
Differentiation Complex (Figure S1H and Table S3C). Thus, enhancers are very 
dynamic during the linear transition of EpSCs towards differentiated keratinocytes 
(Cavazza et al., 2016). 
 
Intriguingly, both Dnmt3a and Dnmt3b were predominantly located at active 
enhancers (Figure 1A–D). Dnmt3a displayed sharp peaks at the center of its target 
enhancers, whereas Dnmt3b had broader peaks that occupied the enhancer center and 
body (Figures 1A, 1B, 2C, and 2D). Enhancers can be subclassified as two types: 
typical enhancers, which are bound by a small number of transcription factors and 
contain sharp peaks of H3K4me1 and H3K27ac, and super-enhancers (SEs), which 
span approximately 20 kb and are cobound by several transcription factors (Hnisz et 
al., 2013). SEs define the pluripotency network in embryonic stem cells and the 
corresponding cellular fate in adult tissues (Hnisz et al., 2013). Based on the size 
distribution of H3K27ac, we identified 12,930 active typical enhancers, and 315 
intergenic SEs, in human EpSCs (Figure 1E). Dnmt3a occupied 981, and Dnmt3b, 
497, typical enhancers. However, both proteins preferred large, distal regulatory SE 
domains (Figure 1F and Table S4A). Enhancers bound by Dnmt3a or Dnmt3b 
expressed significantly higher levels of enhancer RNAs and their associated mRNAs 
than enhancers not bound by either protein (Figure 1G and Table S4B). Still, the 
positive correlation between eRNA and mRNA levels and Dnmt3 binding was more 
pronounced with Dnmt3b than Dnmt3a. Gene ontology (GO) based on proximity 
analysis indicated that, in stem cells, SEs with either Dnmt3a or Dnmt3b regulated 
genes involved in cell proliferation, keratinocyte fate, epidermal morphogenesis, or 
adhesion of stem cells to their ECM (Figures S1I and SJ), while those with Dnmt3a in 
differentiated keratinocytes were related to genes predominantly involved in 
epidermal differentiation (Figure S1J).  
 
Dnmt3a and Dnmt3b are Recruited to Active Enhancers in an H3K36me3-
Dependent Manner 
The PWWP domain of Dnmt3a and Dnmt3b interacts with H3K36me3, a chromatin 
mark associated to transcriptional elongation, to bind to gene bodies (Baubec et al., 
2015; Dhayalan et al., 2010; Morselli et al., 2015; Rondelet et al., 2016). Although 
H3K36me3 is differentially enriched at active enhancers, correlating with enhancer 
activity (Zetner et al., 2011), its role at these regulatory regions is not known. Indeed, 
ChIP-seq of H3K36me3 in human EpSCs indicated that enhancers bound by Dnmt3a 
or Dnmt3b contained significantly higher levels H3K36me3 than the cohort of active 
enhancers not bound by either protein (Figure 2A). Knockdown of the 
methyltransferase Setd2, which methylates H3K36, strongly reduced the localization 
of Dnmt3a and Dnmt3b to their respective target enhancers (Figure 2B–D). Thus, 
Dnmt3a and Dnmt3b may require H3K36 trimethylation to bind to their target 
enhancers.  
 
To test how Dnmt3a and Dnmt3b bind their target enhancers, we first infected 
primary human keratinocytes with a RFP lentiviral inducible shRNA against 
endogenous Dnmt3a and Dnmt3b (Figure 2E). After the endogenous proteins were 
knocked down, cells were infected with a retroviral vector expressing GFP and a 
wild-type version of Dnmt3a1 or Dnmt3b1 (the most abundant isoforms expressed in 
human EpSCs) (Table S1A), or with a mutanted PWWP domain unable to bind to 
H3K36me3 (Baubec et al., 2015; Chen et al., 2004). Double RFP/GFP–positive cells 
were then FACS-sorted and analyzed by ChIP-qPCR  for Dnmt3a or Dnmt3b binding 
at target enhancers (Figure 2E). Wild-type versions, but not the PWWP mutants, 
efficiently bound their target enhancers, indicating that both proteins directly interact 
with these regulatory elements by associating with H3K36me3 through the PWWP 
domain (Figure 2E). We confirmed that the Dnmt3b-PWWP mutant could no longer 
bind to gene bodies, as previously reported for mouse embryonic stem cells (Baubec 
et al., 2015) (Figure 2E). Conversely, the Dnmt3A1-PWWP mutant bound its target 
promoters, which are devoid of H3K36me3 (Figures 2E and Table S1). Wild-type and 
PWWP mutants of Dnmt3a and Dnmt3b were expressed at equal levels (Figure 2F).  
 
Dnmt3a Interacts with p63 to Associate to its Target Enhancers 
As Dnmt3a binds to the center of the enhancers, we next asked whether it functionally 
interacts with specific transcription factors to regulate enhancer activity. A 
transcription factor binding motif search revealed that enhancers bound by Dnmt3a 
were enriched for AP1, p63, TCF3, and MYC motifs (Figure 2G). p63, a master 
regulator of the ectodermal fate, interacts with enhancers to regulate a gene 
expression program required for epidermal homeostasis (Kouwenhoven et al., 2015) 
(Figure 2H). Similar to Dnmt3a, p63 showed a preference for SEs, both in stem cell 
and differentiated states (Kouwenhoven et al., 2015). Approximately 50% of the 
Dnmt3a-associated enhancers were bound by p63 in EpSCs, which corresponded to 
those regulating the expression of genes involved in keratinocyte proliferation and 
identity (Figure 2I).  
 
Immunoprecipitation studies indicated that both endogenous proteins directly interact 
in primary human keratinocytes (Figure 2J). p63 depletion significantly reduced the 
localization of Dnmt3a at numerous target enhancers, as determined by ChIP-qPCR 
(Figures 2K–2L). Thus, Dnmt3a and p63 physically and functionally interact at 
enhancers to regulate EpSC function.  
 
Dnmt3a and Tet2 Maintain 5-hmC at Active Enhancers in Human EpSCs 
In EpSCs, enhancers bound by Dnmt3a were always within a valley of DNA 
methylation yet contained high levels of DNA hydroxymethylation, as compared to 
those bound by Dnmt3b or not bound by either protein (Figures 3A-B). In addition, 
enhancers decorated by Dnmt3a during EpSC differentiation acquired higher levels of 
5-hydroxymethylcytosine (5-hmC) (Figure S2A–B). Knockdown of Dnmt3a 
significantly and specifically reduced 5-hmC levels at the center of its target 
enhancers, but had no effect on 5-hmC levels at enhancers bound by Dnmt3b or not 
bound by Dnmt3a (Figure 3B). Dnmt3a could promote the methylation of its target 
enhancers, which are then hydroxymethylated to permit their active state. To test this, 
we first verified that only Tet2 (of the three Tet proteins that catalyze DNA 
hydroxymethylation) was highly expressed in human EpSCs (Table S1A). We then 
tested whether Tet2 depletion would reveal the DNA methylation deposited by 
Dnmt3a at its target enhancers. Complete Tet2 depletion severely compromised EpSC 
viability (data not shown). Cells tolerated a 50% knockdown of Tet2 expression 
(Figure S2D), which also slightly but significantly increased the level of DNA 
methylation uniquely at the Dnmt3a-bound, but not Dnmt3b-bound or unbound, 
enhancers (Figures 3C–3D).  
 
To determine whether the methyltransferase domain of Dnmt3a was important for the 
hydroxymethylation of its target enhancers, we depleted primary keratinocytes of 
endogenous Dnmt3a, ectopically expressed either wild-type Dnmt3a1 or a 
methyltransferase dead mutant (methyl mut), and then measured the levels of 5-hmC 
at Dnmt3a target enhancers (Chen et al., 2004) (Figures 3E and S4C). Indeed, 
overexpression of Dnmt3a promoted EpSC differentiation, as determined by a 
reduced clonogenic potential and an increased expression of terminal differentiation 
genes (Figures 3E, 3F, S1A, and S1B). Following ectopic expression of Dnmt3a, we 
measured the levels of 5-hmC at those Dnmt3a-bound enhancers in differentiated 
keratinocytes. Loss of endogenous Dnmt3a reduced 5-hmC levels at these enhancers, 
further confirming our hMeDIP-seq results (Figure 3E). Importantly, only ectopically 
expressed wild-type Dnmt3a, but not the methyltransferase mutant, rescued the loss of 
5-hmC induced by knockdown of endogenous Dnmt3a (Figure 3E). Overexpression 
of the methyltransferase mutant failed to induce epidermal differentiation, further 
indicating that the catalytic domain of Dnmt3a is essential for its function in 
epidermal cells (Figures 3E-F). Thus, these results strongly suggest that Dnmt3a and 
Tet2 cooperate to subsequently induce DNA methylation and hydroxymethylation of 
enhancers to regulate EpSCs homeostasis. 
 
Dnmt3b Promotes DNA Methylation Along Active Enhancers 
Dnmt3b binding to the enhancer body correlated with higher levels of DNA 
methylation and lower levels of DNA hydroxymethylation as compared to the 
Dnmt3a-bound enhancers or those bound by neither protein (Figures 3B and 3H). 
Dnmt3b depletion in EpSCs had no effect on DNA hydroxymethylation at or around 
its target enhancers (Figure 3B) but significantly lowered the amount of DNA 
methylation along the enhancer (Figure 3I), reminiscent of the known role of Dnmt3b 
in gene body methylation. This effect was not observed after Dnmt3a knockdown 
(Figure 3I). Dnmt3b is recruited to gene bodies in different cell types and promotes 
genic DNA methylation in a manner dependent on histone H3K36me3 (Baubec et al., 
2015; Mikkelsen et al., 2007; Morselli et al., 2015). Our results show that Dnmt3b 
spanned the entire gene body of a specific group of genes in EpSCs as well (Figures 
S3A–S3C). These large domains of Dnmt3b significantly correlated with high mRNA 
expression and broad areas of genic H3K4me3, which confer transcriptional 
consistency and robustness (Benayoun et al., 2014) (Figures S3B and S3C). These 
genes defined the stem cell signature in EpSCs as well as the differentiated signature 
in differentiated keratinocytes (Figure S3E and Table S4C). In general, broad genic 
occupancy by Dnmt3b correlated with high levels of gene body DNA methylation 
(Figure S3F), and Dnmt3b depletion significantly reduced genic DNA methylation 
(Figure S3G).  
 
Depletion of Setd2, the methyltransferase that deposits H3K36me3, significantly 
reduced binding of Dnmt3b to gene bodies and to enhancers (Figures 3G, S3H, and 
S3I). Hence, Dnmt3b is required to promote gene body and enhancer body DNA 
methylation, which correlates to transcription of both regions.  
 
Dnmt3a and Dnmt3b Promote Enhancer Activity and are Required for Human 
EpSC Homeostasis 
Changes in DNA methylation or hydroxymethylation caused by knockdown of 
Dnmt3b or Dnmt3a, respectively, correlated with reduced enhancer activity, as 
measured by transcribed enhancer RNA levels, as well as reduced H3K27ac levels 
(Figures 4A–4C and Table S4D). This effect was observed in typical enhancers and 
SEs bound by Dnmt3a or Dnmt3b (Figures 4A–4C). For instance, Dnmt3a and 
Dnmt3b associated with an intragenic enhancer recently identified to drive the 
expression of Np63 (Antonini et al., 2015), and their depletion in EpSCs also 
decreased the activity of a luciferase reporter containing it (Figures S2C). Specificity 
of Dnmt3a or Dnmt3b binding to enhancers was confirmed in Dnmt3a- or Dnmt3b-
depleted stem cells by ChIP-seq (Figure S2E).  
 
We next asked whether modulating the expression of either Dnmt3a or Dnmt3b 
affects self-renewal and/or differentiation of EpSCs. Dnmt3b predominantly 
associates to enhancers and gene bodies of genes involved in the self-renewal and 
interaction of EpSCs with their niche; differentiation reduces its expression and 
genomic binding. Dnmt3a positively regulates expression of genes involved in stem 
cell proliferation, and interacts with the extracellular matrix via its association with 
enhancers. Upon epidermal differentiation, its genomic binding shifts to activate 
enhancers that promote expression of genes that drive epidermal differentiation. We 
first performed an in vivo competition assay between primary human keratinocytes, 
depleted or not for Dnmt3a or Dnmt3b, that had been transplanted into 
immunocompromised mice; keratinocytes were GFP-tagged, and the shRNA vectors 
were RFP tagged (Figure 4D). Four weeks after transplanting, GFP-positive cells and 
RFP-shControl cells contributed equally to all layers of the reconstituted epithelium. 
However, Dnmt3a-KD and Dnmt3b-KD cells barely contributed to the basal layer and 
were predominantly detected in the differentiated strata of the epithelium (Figure 4E).  
Furthermore, knockdown of either protein impaired the self-renewing potential of 
human EpSCs, as determined by a significant reduction in their clonogenic potential 
in culture (Figures 4F, S4A, and S4B). These changes were accompanied by an 
increased expression of genes involved in epidermal terminal differentiation, and a 
decreased expression of those involved in stem cell proliferation and adhesion to the 
ECM (Figures 4G–4I and Table S4D). Expressions of genes closest to the enhancers 
bound by Dnmt3a/3b were affected by depletion of Dnmt3a/3b (Figure 4H).  
EpSCs depleted of Dnmt3a or Dnmt3b differentiated in the absence of any pro-
differentiation stimulus. However, Dnmt3a expression increases during epidermal 
differentiation (Figures S1A-B), and ectopic expression of wild-type Dnmt3a1 
induced spontaneous differentiation in EpSCs (Figure 3E). Dnmt3a genomic 
localization shifted from enhancers that regulate the expression of genes involved in 
stem cell proliferation to those that regulate differentiation genes. Driving EpSCs to 
differentiate by raising the calcium concentration in the medium led to those depleted 
of Dnmt3a—but not of Dnmt3b—to express lower levels of epidermal differentiation 
markers than differentiating control cells (Figure 4J). Thus, Dnmt3a has a dual role in 
maintaining EpSC self-renewal, while also promoting differentiation once basal cells 
have committed to differentiate.  
 
Discussion 
We determined that Dnmt3a and Dnmt3b positively regulate gene expression through 
non-overlapping functions at regulatory elements via distinct mechanisms. Dnmt3b 
promotes methylation not only at genes but also at enhancer body DNA, both of 
which are required to sustain high transcriptional activity of mRNA or eRNA, 
respectively (Hon et al., 2013; Rasmussen et al., 2015). Interestingly, enhancer RNAs 
increase the association of transcription factors with enhancers (Sigova et al., 2015). 
Hence, the positive impact of Dnmt3a and Dnmt3b on the production of enhancer 
RNAs might contribute to the overall robustness of enhancer activity.  
 
Dnmt3a/b recruitment to enhancers depends on the presence of H3K36me3. 
Intriguingly, Dnmt3a requires p63 to bind to its target enhancers. It remains to be 
determined how and why Dnmt3a and Dnmt3b preferentially associate to some 
enhancers, and to some gene bodies, at the genome-wide scale. For instance, Dnmt3a 
decorates gene bodies of neurogenesis genes in murine neural stem cells, whereas 
Dnmt3b (but not Dnmt3a) interacts with gene bodies in murine and human embryonic 
stem cells (Wu et al., 2010).  
 
We also observed the same pattern of Dnmt3a and Dnmt3b genomic localization at 
enhancers, and of Dnmt3b at gene bodies, in primary human dermal fibroblasts, 
indicating that their interaction with enhancers is likely to be a general function in 
somatic cells (Figures S4D). However, there was virtually no overlap between the 
enhancers bound by either protein, nor the genes and biological functions regulated by 
these, in human primary fibroblasts or human EpSCs, further indicating that their 
specific genomic localization is highly influenced by the cellular context (Figures 
S4E–S4G). Considering that deregulation of Dnmt3a and Dnmt3b affects 
tumourigenesis in several tissues (Timp and Feinberg, 2013; Witte et al., 2014), these 
newly identified functions might have important roles in regulating the homeostasis 
and tumour development of these different tissues.  
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Figure Legends 
Figure 1. Dnmt3a and Dnmt3b Bind at the Most Active Enhancers in EpSCs and 
Differentiated Keratinocytes. (A, B) ChIP-seq coverage depth (per bp per peak per 
10 million mapped reads) of Dnmt3a/ Dnmt3b, H3K27ac, and H3K4me1 around the 
Dnmt3a/Dnmt3b peaks (–8 kb to +8 kb) in stem cells and differentiated 
keratinocytes. (C, D) Typical enhancer and super-enhancer (SE) bound by Dnmt3a or 
Dnmt3b. (E) Distribution of the H3K27ac signal (total reads) across all enhancers. (F) 
Fold-differences of Dnmt3a and Dnmt3b (total signal and density) between SEs and 
typical enhancers. Fold-changes refer to the ratio of the respective means between 
SEs and typical enhancers. (G) Boxplots depicting enhancer RNA and mRNA levels 
of closest genes, given in log (FPKM), for enhancers bound or not by Dnmt3a and/or 
Dnmt3b in stem cells and differentiated keratinocytes. p values were calculated using 
a Wilcoxon test; from left to right, p = 3.5  10–6, p = 0.02, p < 2.2  10–16, p < 2.2  
10–16. 
 
Figure 2. Dnmt3a/b are Recruited to Active Enhancers Through Their 
H3K36me3 Binding. (A) ChIP-seq coverage depth of H3K36me3 in stem cells 
around the intergenic enhancers (–8 kb to +8 kb) bound or not by Dnmt3a and/or 
Dnmt3b, as indicated. (B) Western blot of H3K36me3 levels in EpSCs infected with 
shCTRL or a shSETD2 lentiviral vector. (C) ChIP-seq signals at intergenic enhancers 
bound by Dnmt3a in stem cells infected with an shCTRL or shSETD2 lentiviral 
vector; p < 2.2  10–16. (D) ChIP-seq signals at intergenic enhancers bound by 
Dnmt3b, in cells infected with an shCTRL or shSETD2 lentiviral vector; p < 2.2  10–
16. (E) Schema of FACS isolation of doubly-infected human EpSCs, expressing both 
inducible shRNAs against the 3-UTR of Dnmt3a1 or Dnmt3b1 and the combined 
ectopic expression of the wild-type (WT) or PWWP (WPST) mutant version. 
Lower panel: triplicates of Dnmt3a/b ChIP-qPCR, using 500,000 cells for each 
condition. Enrichment was normalized to a negative intergenic region. (F) Western 
blot of Dnmt3a and Dnmt3b in human EpSCs infected with empty vector (EV), WT, 
methyltransferase mutant, or PWWP mutant Dnmt3a or Dnmt3b-expressing vectors. 
(G) Transcription Factor Motif analysis using DREME online software at the 
intergenic enhancers bound by Dnmt3a. (H) Examples of enhancers bound both by 
tp63 and Dnmt3a. (I) Intersection between enhancers bound by tp63 and Dnmt3a, and 
relative gene ontology analysis of the associated genes to the cobound enhancers. (J) 
Immunoprecipitates of Dnmt3a and Dnmt3b, from total cell lysates from human 
EpSCs, and western blot against tp63. (K) Western blot against tp63 in shCtrl or in 
shtp63 human EpSCs. (L) Dnmt3a enrichment at intergenic enhancers cobound with 
tp63, showing ChIP qRT-PCR results in shCtrl and in shtp63 human EpSCs. 
 
Figure 3. Dnmt3a and Tet2 Maintain High Levels of 5-hmC at Enhancers, 
whereas Dnmt3b Maintains High Levels of DNA Methylation Surrounding the 
Enhancer Center. (A) Relative methylation score (CpG count) measured around 
enhancers bound or not by Dnmt3a. p < 2.2  10–16. (B) Global levels of 5-hmC at 
enhancer center (–2 Kb, +2 Kb) quantified by HOMER software in EpSCs infected 
with shCTRL, shDnmt3a, or shDnmt3b, at enhancers bound by Dnmt3a, Dnmt3b, or 
neither. (C) 5-methylcytosine (5-mC) levels around enhancers bound by Dnmt3a in 
shCTRL and shTET2 EpSCs; p < 2.2  10–16. (D) 5-mC levels around enhancers not 
bound by Dnmt3a in shCTRL and shTET2 EpSCs. (E) Representation of clonogenic 
assay experiment of human EpSCs expressing WT Dnmt3a1, or a methyltransferase-
dead mutant, compared to empty vector (EV). (F) Quantification of colonies from 
clonogenic assay of EV, Dnmt3a1, or Dnmt3a1 methyltransferase mutant from three 
independent biological replicates. (G) Scheme method for FACS isolating doubly-
infected human keratinocytes expressing GFP-tagged inducible shRNAs against 3-
UTR of Dnmt3a1, and ectopic expression of WT or the methyltransferase-dead 
mutant Dnmt3a (PCVD) co-expressing RFP. Lower panel: results from triplicate 
experiments of 5-hydroxyMedIP (for 5-hmC) qRT-PCR using 100,000 cells per 
condition. Enrichment was calculated by normalizing the value to GAPDH at TSS, a 
negative region for DNA methylation, and for DNA hydroxymethylation. (H) MeDIP-
seq was used to determine 5-mC levels around enhancers bound or not bound by 
Dnmt3b. CpG methylated counts at enhancers bound or not bound by Dnmt3b 
(p < 0.0001) (right). (I) Relative methylation score measured around enhancers (–5 
kb, +5 kb) in shCTRL and shDnmt3b EpSCs (p < 0.0008) (left), and in shCTRL and 
shDnmt3a EpSCs (p = 0.08) (right).  
 
Figure 4. Depletion of Dnmt3a and Dnmt3b Decreases the Activity of its Target 
Enhancers. (A, B) Boxplots depicting the enhancer RNA levels, given as log 
(FPKM), from enhancers bound by Dnmt3a and Dnmt3b in wild-type and knockdown 
cells. p values were calculated using Wilcoxon-signed ranked test; from left to right, 
p = 1.05  10–5, 0.943, 0.003, and 2.3  10–10. (C) Boxplots depicting levels of 
H3K27ac in CTRL and KD cells around typical enhancers and SEs bound by Dnmt3a 
(two left) and Dnmt3b (two right). p values were calculated using a two-sample 
Kolmogorov-Smirnov test; from left to right, p < 2.2  10–16, p = 7.3  10–15, 
p = 0.00035, p = 0.04; ***p < 0.001. (D) Schematic representation of competitive 
skin reconstitution assay between GFP EpSCs versus shRNA-RFPs EpSCs (n = 3 for 
each shRNA). (E) Representative GFP/RFP fluorescent confocal images of the human 
reconstituted epithelia from the transplanted area of the three sets of transplants 
described in D. White bar represents 50 μm. Right, percentages of RFP and GFP cells 
in the basal layer of shCtrl or shDnmt3a/3b transplants. (F) Colony formation of 
Dnmt3a- or Dnmt3b-deficient EpSCs. Right, quantification (n = 4) of the colonies 
formed by Dnmt3a/b using two constitutive shRNA for each protein. (G) 
Immunofluorescence of involucrin, integrin 6, Dnmt3a, or Dnmt3b in shCTRL and 
shDnmt3a/3B EpSCs. (H) Boxplots depicting mRNA expression (from three 
independent biological replicates) of closest genes to enhancers bound by Dnmt3a in 
shCtrl and in shDnmt3a human EpSCs (left), and of closest genes to enhancers bound 
by Dnmt3b in shCtrl and shDnmt3b cells (right): p values were calculated using a 
Wilcoxon signed-ranked test; left, p < 2.2  10–16; right, p = 7.8  10–13 . (I) GO 
analysis of genes downregulated (left) or upregulated (right) in shDnmt3a or in 
shDnmt3b EpSCs. (J) Relative mRNA expression levels of differentiation markers in 
control cells and shDnmt3a and shDnmt3b during keratinocytes differentiation. 
Expression levels were normalized to the housekeeping gene PUM1. 
  
METHODS 
ChIP-seq 
ChIP was performed as previously described (Morey et al., 2012). Keratinocytes were 
trypsinized and crosslinked in 1% formaldehyde for 10 min at room temperature. To 
immunoprecipitate transcription factors, 2 mg of protein and 100 g of 
immunoprecipitated histone/histone modifications were used. Antibodies (10 g for 
Dnmt3a/3b and 3 g for histone modifications) were incubated overnight with 
chromatin in ChIP buffer. Immunocomplexes were recovered with 30 l of protein A 
bead slurry (Healthcare, 17-5280-01). Antibodies used for ChIP or MedIP were 
Dnmt3a (SantaCruz H-295), Dnmt3b (Novus Biotechnology, NB100-266), H3K27ac 
(Merck Millipore, 07-360), H3K4me1 (Abcam, ab8895), and H3K4me3 (Diagenode, 
C15410003-50), and H3K36me3 (Abcam, ab9050). Libraries for sequencing were 
prepared using NEBNext Ultra DNA Library Prep Kit for Illumina (E7370L) 
following manufacturer's instructions.  
 
MeDIP and hMeDIP Sequencing 
Purified genomic DNA (500 ng) was sonicated to obtain fragments of 300–700 bp. 
Adaptors from the NEBNext Ultra DNA Library Prep Kit for Illumina were added to 
the fragmented DNA. Fragmented DNA was incubated 2 hr with 1 g of 5-
methylcytosine (Eurogentec, BI-MECY-0100) or 5-hmC (Active Motif, 39769). 
Immunocomplexes were recovered using 8 l of Dynabeads Protein A (Life 
Technologies) for 2 hr. Amplified libraries were prepared using NEBNext Ultra DNA 
Library Prep Kit for Illumina (E7370L) following manufacturer's instructions. 
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SUPPLEMENTARY INFORMATION 
 
Figure S1 related to Figure 1. Dnmt3a and Dnmt3b Expression is Differentially 
Regulated During Human EpSC Differentiation mirroring dynamic behavior of 
enhancers between Human EpSC and differentiated keratinocytes. (A) RT-qPCR 
results confirming the differential expression of Dnmt3a and Dnmt3b during EpSC 
differentiation. RNA levels are normalized with respect to the PUM1 housekeeping 
gene (n = 5). (B) Western blot of EpSCs and differentiated keratinocytes for Dnmt3a, 
Dnmt3b. (C) Number of Dnmt3a or Dnmt3b peaks identified using Deseq2 in EpSCs 
and differentiated keratinocytes. (D) Dnmt3a and Dnmt3b ChIP-seq signal intensity at 
peaks defined as common using DeSeq2 in EpSCs and differentiated keratinocytes  
(E) Heatmap for RNA-seq (F) or ChIP-seq binding profiles for histone marks, Medip-
Seq and 5-HydroxyMedip-Seq in EpSCs and differentiated keratinocytes. (G) Pearson 
correlation plot of ChIP-seq for H3K4me1 and H3K27ac replicates in EpSCs and in 
differentiated keratinocytes. (H) Upper panel, overview of active enhancer 
(H3K4me1+ H3K27ac+) dynamics during differentiation of EpSCs to differentiated 
keratinocytes. Differentially enriched enhancers were calculated with DeSeq2 using 
three biological replicates for each histone mark. Lower panel, gene ontology (GO) 
analysis (identified by proximity) of active enhancers in either EpSCs or 
differentiated keratinocytes or in both. (I) Gene ontology of the genes closest to 
super-enhancers bound by Dnmt3a/b in EpSCs. (J) Gene ontology and mRNA 
expression (small boxes) of the genes closest to the enhancers bound by Dnmt3a in 
EpSCs (left) or differentiated keratinocytes (right).  
 
Figure S2 related to Figure 3. The Dynamic Binding of Dnmt3a at Enhancers 
Correlates with High Levels of 5-hmC. (A) Boxplots depicting hMeDIP-seq 
coverage depth (per bp per peak per 10 million mapped reads) at the intergenic 
enhancers bound by Dnmt3a only in EpSCs (left) or differentiated keratinocytes 
(right) (both with p < 0.0001). (B) Upper panel, UCSC genome browser screenshot of 
two enhancers bound in differentiated keratinocytes by Dnmt3a. All tracks show 
normalized and scaled raw sequencing reads. Lower panel, hMeDIP-seq coverage 
depth (per bp per peak per 10 million mapped reads) at the intergenic enhancers 
proximal to KRT1 (right, p = 5.62 × 10–5). (C) Intragenic ΔNp63 enhancers bound by 
Dnmt3a and Dnmt3b, recently shown to drive ΔNp63 expression in embryonic and 
adult murine basal epidermal keratinocytes. Lower panel: C38C40-Luc enhancer 
activity were analyzed in shCTRL and Dnmt3a or Dnmt3b knockdown human stem 
cells after 48 hr of plasmid transfection. Data are expressed relative to the TK 
promoter activity used as control (*p ≤ 0.05; n = 3). (D) Western blot for Tet2 protein 
and tubulin loading control in shCTRL and shTet2 in human EpSCs. (E) Enhancer 
binding was confirmed in two biological replicates. ChIP-seq coverage depth (per bp 
per peak per 10 million mapped reads) of Dnmt3a and Dnmt3b in shCTRL or 
Dnmt3a/b knockdown EpSCs. 
 
 
Figure S3 related to Figure 3. Dnmt3b Spans Large Domains at the Gene Body 
of Highly Expressed Genes in an H3K36me3-dependent Manner. (A) UCSC 
screenshots of RNA-seq, H3K4me3, and ChIP-seq (using Dnmt3a, Dnmt3b, or input) 
of examples of gene body binding by Dnmt3b in stem cells and differentiated 
keratinocytes. (B) Percentage of genomic overlap between Dnmt3a/b binding sites 
with H3K4me3 peak breadth. (C) Localization of H3K4me3 and Dnmt3b ChIP-seq 
signal in EpSCs, at the genes covered by the broadest domains of Dnmt3b. (D) RNA-
seq expression values (log(FPKM)), both in EpSCs and in differentiated 
keratinocytes, of the genes bound by the broadest domains of Dnmt3b as compared to 
the all genes. Panel D, left side, p < 2.2 × 10–16; right side, p = 1.579 × 10–6. (E) Gene 
ontology analysis of genes covered by the broadest domains of Dnmt3b in EpSCs or 
in differentiated keratinocytes. (F) 5-methylcytosine levels at genes marked by the 
broadest and shortest domains of Dnmt3b. p < 2.2 × 10–16. (G) Relative methylation 
score measured at gene bodies bound by Dnmt3b in EpSCs infected with shCTRL 
vector or shDnmt3b vector (p < 0.001). (H) Depletion of Dnmt3b in EpSCs confirms 
the specificity of Dnmt3b binding to the gene bodies, as determined by ChIP-seq in 
shCTRL- and Dnmt3b-knockdown cells.  (I) ChIP-seq coverage depth (per bp per 
peak per 10 million mapped reads) of Dnmt3b in shCTRL and SETD2 knockdown 
cells. 
 
Figure S4 related to Figure 3. (A) Western blot of Dnmt3a and Dnmt3b proteins in 
control cells or cells infected with constitutive (left) or inducible (right) shRNA 
constructs targeting the expression of Dnmt3a or Dnmt3b. (B) Representative images 
of the clonogenic assay and quantification of colonies formed by human EpSCs 
infected with doxycycline-inducible shRNA vectors expressing shRNAs against 
Dnmt3a or Dnmt3b. (C) MeDIP-qPCR using 100,000 sorted RFP+GFP+ cells, 
expressing the shRNAs against endogenous Dnmt3a and the cDNA to ectopically 
express wild-type Dnmt3a1, or the methyltransferase mutant version (PCèVD). 
Enrichment at the promoter region of the STX6, CASC4, and GET4 genes was 
calculated by normalizing the value of the GAPDH TSS, a region negative for DNA 
methylation. (D) Left panel: ChIP-seq coverage depth (per bp per peak per 10 million 
mapped reads) of input, H3K4me1, H3K27ac, Dnmt3a, or Dnmt3b in human primary 
dermal fibroblasts. Right panel: UCSC genome browser screenshot of examples of 
Dnmt3a/b binding at active enhancers in human primary dermal fibroblasts. (E) 
Number of peaks overlapping between ChIP-seq of Dnmt3a and Dnmt3b in EpSCs 
and in primary human dermal fibroblasts. (F) Gene ontology of genes closest to 
enhancers (H3K4me1 and H3K27ac ChIP-seq from dermal fibroblasts obtained from 
the ENCODE database) bound by Dnmt3a or Dnmt3b. (G) Left panel, ChIP-seq 
coverage depth (per bp per peak per 10 million mapped reads) of input and Dnmt3b in 
active gene bodies in primary human dermal fibroblasts. Right panel, gene ontology 
of genes bound by Dnmt3b at gene bodies. 
 
  
SUPPLEMENTARY TABLES 
 
Table S1 related to Figure S1 and Figure 1. It contains the fpkm values of genes 
and all specific isoforms expressed in epidermal stem cells and differentiated 
keratinocytes.  
 
Table S2 related to Figure S1 and Figure 1. Sheet A, contains the genomic 
coordinates of the ChIP-seq peaks of Dnmt3a and Dnmt3b in stem cells and 
differentiated keratinocytes used in the manuscript to describe the regulation of 
Dnmt3a and Dnmt3b in EpSC homeostasis. Sheet B contains the Pearson Correlation 
coefficient of the two biological replicates of Dnmt3a and Dnmt3b Chip-seq. 
 
Table S3 related to Figure S1, Figure S3, Figure 1, Figure 2 and Figure 3. Sheet 
A contains the genomic coordinates of the ChIP-seq peaks of H3K4me1, H3K4me3 
and H3K27ac in stem cells and differentiated keratinocytes.  Sheet B contains the 
consensus enhancers found in EpSC and in Differentiated Keratinocytes using three 
biological replicates and used for DeSeq2 differential enrichment analysis. Sheet C 
shows the list of genes closest to active enhancers in epidermal stem cells, and 
enhancers that become de novo active or remain active upon keratinocyte 
differentiation, using standard MACS2 peak calling.  
 
 
Table S4 related to Figure 4. Sheet A contains data classifying enhancers into 
typical and super-enhancers in stem cells and for differentiated keratinocytes. It also 
contains the signal and read density data of Dnmt3a and Dnmt3b at the enhancers. 
Sheet B contains enhancer RNA values in stem cells and differentiated keratinocytes, 
and in knockdown cells, respectively.  
Sheet C, relates to Figure S3 and contains the lists of genes that are covered by broad 
domains of Dnmt3b in stem cells and differentiated keratinocytes. 
Sheet D, relates to Figure4 and contains the lists of genes that are downregulated or 
upregulated in Dnmt3a and Dnmt3b knockdown cells. 
 
  
SUPPLEMENTARY METHODS 
 
Human EpSC Culture and Calcium-induced Differentiation 
Human EpSCs were isolated independently from three neonatal foreskin samples and 
cultured with a feeder layer of fibroblasts (J2-3T3) as described previously (Janich et 
al., 2013). Undifferentiated keratinocytes were grown in keratinocyte serum-free 
medium (KSFM) with supplements as indicated by the manufacturer (GIBCO). For 
calcium-induced differentiation, KSFM was exchanged for EMEM (Lonza) 
supplemented with 8% chelated FBS, EGF (10 ng/ml), 1% penicillin/streptomycin, 
and 1.2 mM CaCl2, once cells had reached 70% confluence. After 48 hr, differentiated 
keratinocytes were collected for analysis. 
 
Lentiviral Infections 
EpSCs growing in KSFM media were infected with precipitated lentiviral particles 
produced by 293T cells and transfected with the above-mentioned plasmids, as 
previously described (Janich et al., 2013; Luis et al., 2011). Cells were collected for 
RNA extraction or ChIP assay after 5 to 7 days of puromycin selection. 
 
Chromatin immunoprecipitation–sequencing (ChIP-seq) 
ChIP was performed as previously described (Morey et al., 2012). Briefly, EpSCs and 
differentiated keratinocytes were trypsinized and crosslinked in 1% formaldehyde for 
10 min at room temperature. Crosslinking was quenched with 0.125 M glycine. 
Pelleted cells were lysed in 1 ml ChIP buffer (2:1 solution of 100 mM NaCl, 50 mM 
Tris-HCl, 5 mM EDTA, 0.5% SDS, 100 mM NaCl, 5 mM EDTA, and 5% Triton X-
100) and sonicated for 15 min in a Bioruptor (Diagenode). Soluble material was 
quantified by Bradford assays. To immunoprecipitate transcription factors, 2 mg of 
protein and 100 µg of immunoprecipitated histone/histone modifications were used. 
Antibodies (10 µg for Dnmt3a/3b and 3 µg for histone modifications) were incubated 
overnight with the chromatin in ChIP buffer. Immunocomplexes were recovered with 
30 µl of protein A bead slurry (Healthcare, 17-5280-01).  Immunoprecipitated 
material was washed three times with low salt buffer (50 mM HEPES pH 7.5, 140 
mM NaCl, 1% Triton) and 1× with high salt buffer (50 mM HEPES pH 7.5, 500 mM 
NaCl, 1% Triton). DNA complexes were de-crosslinked at 65°C overnight, and DNA 
was then eluted in 50 µl of water using the PCR purification kit (QIAGEN). 
Antibodies used for ChIP or MedIP were Dnmt3a (SantaCruz H-295), Dnmt3b 
(Novus Biotechnology, NB100-266), H3K27ac (Merck Millipore, 07-360), H3K4me1 
(Abcam, ab8895), and H3K4me3 (Diagenode, C15410003-50), and H3K36me3 
(Abcam, ab9050). Libraries for sequencing were prepared using NEBNext Ultra DNA 
Library Prep Kit for Illumina (E7370L) following the manufacturer's instructions.  
 
MeDIP and hMeDIP sequencing 
Purified genomic DNA (500 ng) from cells was sonicated to obtain fragments of 300–
700 bp. Adaptors from the NEBNext Ultra DNA Library Prep Kit for Illumina were 
added to the fragmented DNA. DNA was denatured for 10 min at 99°C and cooled 
down to avoid re-annealing. Fragmented DNA was incubated 2 hr with 1 µg of 5-
methylcytosine (Eurogentec, BI-MECY-0100) or 5-hydroxymethylcytosine (Active 
Motif, 39769). Immunocomplexes were recovered using 8 µl of Dynabeads Protein A 
(Life Technologies) for 2 hr. Purified DNA was extracted using QIAquick MinElute 
(Qiagen). Amplified libraries were prepared using NEBNext Ultra DNA Library Prep 
Kit for Illumina (E7370L) following manufacturer's instructions. 
 ChIP-seq Data Processing 
The ChIP-seq datasets were aligned to the Human Genome hg19 using Bowtie 
(version 1.0.1) (Langmead et al., 2009), using the parameters –k 1, –m 1, and –n 2. 
Peak calling of Dnmt3a and Dnmt3b to determine regions of ChIP-seq enrichment 
over the background was done with the MACS version 1.4.1., using parameters –p 
1e–5, –w, –S, and –g hs5. Peaks of the methylation and hydroxymethylation datasets 
were determined similarly, but with the parameter p set to 1e–3. For histone marks, 
the MACS version 2 was used with parameters –broad, -q 0.01, and –g hs. UCSC 
browser tracks (Kent et al., 2002) were created from the MACS wiggle or bedgraph 
output. ChIP-seq peaks were annotated using the annotatePeaks.pl script of the 
HOMER suite (version 4.6) (Heinz et al., 2010) using the UCSC hg19 annotation. 
The coverage depths of different ChIP-seq experiments at specified regions were also 
calculated using the annotatePeaks.pl script. This generates a normalized coverage 
value of different sequencing experiments at equally-spaced bins spanning the region 
of interest. The bin size was set to 25 bp. 
For the differential regulation analysis of ChIP-seq data with replicates, the R package 
DiffBind 
(http://bioconductor.org/packages/release/bioc/vignettes/DiffBind/inst/doc/DiffBind.p
df) was used, with DESeq2 (Love et al., 2014) applied to calculate the differentially 
bound regions using padj < 0.1. The differential regions were called on a set of 
consensus peaks (e.g., peaks present in at least 2 out of 3 replicates for cases with 3 
replicates, and merging peaks for cases with 2 replicates).  
 
RNA Library Preparation and Sequencing 
The library from total RNA from three biological replicates was prepared using the 
TruSeq®Stranded Total Sample Preparation kit (Illumina Inc.) according to the 
manufacturer’s protocol. Briefly, rRNA was depleted from 0.5 µg of total RNA using 
the Ribo-Zero Gold Kit, followed by fragmentation by divalent cations at elevated 
temperature, resulting into fragments of 80–450 nt, with the major peak at 160 
nt.  First-strand cDNA synthesis by random hexamers and reverse transcriptase was 
followed by the second-strand cDNA synthesis, performed in the presence of dUTP 
instead of dTTP. Blunt-ended double-stranded cDNA was 3ʹ-adenylated, and the 3ʹ-
“T” nucleotide at the Illumina indexed adapters was used for the adapter ligation. The 
ligation product was amplified with 15 cycles of PCR. Each library was sequenced 
using TruSeq SBS Kit v3-HS, in paired end-mode with the read length 2 × 76 bp. A 
minimal of 137 million paired-end reads were generated for each sample run in one 
sequencing lane on HiSeq2000 (Illumina, Inc) following the manufacturer’s protocol. 
Images analysis, base calling, and quality scoring of the run were processed using the 
manufacturer’s software Real-Time Analysis (RTA 1.13.48) and followed by 
generation of FASTQ sequence files by CASAVA. 
 
RNA-seq Data Processing 
RNA-seq datasets were aligned to the Human Genome hg19 using the GEM split 
mapper version 7.0 (Marco-Sola et al., 2012) with default parameters. To quantify the 
gene and transcript expression levels, Cufflinks (version 2.1.1) (Trapnell et al., 2010) 
was run with UCSC hg19 reference annotations, providing FPKM (fragments per 
kilobase of exon per million fragments mapped) values. Differentially expressed 
genes were obtained using Cuffdiff from the Cufflinks suite. A q-value cutoff of 
0.001 was used for identifying differentially expressed genes. 
 Enhancer Analysis 
Enhancers were divided into two classes: poised and active. Poised enhancers were 
defined as regions with peaks of H3K4m1 but not of H3K27ac, while active 
enhancers were defined as regions with peaks of both H3K4m1 and H3K27ac. 
Enhancer regions were annotated using the HOMER suite. Enhancer RNA FPKM 
values were calculated by obtaining the number of RNA-seq reads falling within the 
enhancer region and normalizing it by the enhancer length and number of mapped 
reads. To generate the enhancer RNA box plots, only intergenic enhancer regions 
were considered.  
 
Super-enhancer Analysis 
Super-enhancers (SEs) were detected using the ROSE software 
(https://bitbucket.org/young_computation/rose). The software was run with default 
parameters, with peaks of H3K27ac considered as constituent enhancers. Briefly, 
ROSE stitches together enhancer regions within 12.5 kb (default) of one another. The 
stitched enhancer regions were ranked by the H3K27ac signal present in them. From 
the graph of H3K27ac signal versus enhancer rank, the enhancers residing above the 
inflexion point of the curve were designated as SEs, while the rest were designated as 
normal enhancers. ROSE outputs the H3K27ac read density in units of reads-per-
million mapped per bp (rpm/bp) of each stitched enhancer. SE and typical enhancer 
regions were considered to contain Dnmt3A and Dnmt3B if there was an overlap with 
Dnmt3A and Dnmt3B peaks, respectively. To quantify the signal strength of Dnmt3A 
and Dnmt3B in typical enhancers and SEs, the read densities of Dnmt3A, Dnmt3B, 
and the input were calculated in units of rpm/bp of each enhancer region.  For further 
consideration, the background-subtracted density for an enhancer region was required 
to be at least 0.05 rpm/bp. For both typical enhancers and SEs, the mean of the 
background subtracted ChIP-seq signal (total reads) and the mean of the signal 
density was calculated. The fold differences shown in Figure 3 refer to the ratios of 
these means between SEs and typical enhancers.  
 
Relative Methylation Score  
Relative methylation score (RMS) was calculated using the MEDIPS (1) package.  
MEDIPS calculates normalized methylation levels (RMS) by building a linear model 
which represents the dependency of CpG densities and the MeDIP-seq counts across 
the entire range of CpG densities (Lienhard et al., 2014). RMS values were calculated 
using MEDIPS at 100 bp windows across the genome. These values were used to 
calculate the RMS values at enhancers and gene bodies bound by Dnmt3b. The 
function used for this purpose was MEDIPS.selectROIs with the “summarize=avg” 
option; thus the RMS values in the windows inside the enhancers and gene bodies are 
averaged. 
 
Enhancer “body” is defined as the region flanking the enhancer center. It was 
calculated on average for SEs and typical enhancers to be between –/+4 KB from the 
enhancer center. The RMS value of the enhancer body was calculated using unique 
aligned reads at a distance of –/+4KB from the center of enhancer, found by the 
intersection of H3K4me1 and H3K27ac peaks in intergenic regions. 
 
Statistical Significance Tests 
For all boxplots, p values for statistical significance were calculated using a Wilcoxon 
signed-rank test. A two-sample Kolmogorov-Smirmov test was used to calculate the 
statistical significance between coverage density plots. 
 
Immunofluorescence 
Human EpSCs grown on glass coverslips were fixed in 4% paraformaldehyde for 10 
min, permeabilized with 0.5 % Triton/ PBS for 10 min, blocked with 0.25% 
BSA/PBS for 45 min, and stained with primary and secondary antibodies diluted in 
blocking buffer for 60 min at room temperature. Nuclei were counterstained with 
DAPI (Roche). Primary antibodies were anti-involucrin (1:1,000; Abcam, ab68), anti-
DNMT3A (1:100, SantaCruz), and DNMT3B (1:200, Novus Biotech); secondary 
antibodies were anti-rabbit Alexa Fluor 647 and anti-mouse Alexa Fluor 594 (1:500, 
Molecular Probes). Pictures were acquired using a Leica TCS SP5 confocal 
microscope. Protein extracts were analyzed by SDS-PAGE, and western blotting for 
DNMT3a (1:500 SantaCruz) and DNMT3b (1:1000 Novus Biol). 
 
RT-qPCR 
RNA was extracted using TRIzol (SIGMA®) and converted into cDNA by reverse 
transcriptase using the TaqMan Applied Biosystem® kit. Gene expression was 
quantified by quantitative real-time PCR using SYBR Green (Applied Biosystem) 
master mix. 
 
Mutagenesis of Dnmt3a1 and Dnmt3b1 Wild-type Isoforms 
Dnmt3a1 and Dnmt3b1 cDNA isoforms were ordered from Addgene and cloned into 
the pMSCV PIG (Puro-Ires-GFP) retroviral backbone vector. Point mutations were 
inserted using the Agilent Quikchange II XL Mutation Kit using the following 
primers:  
Dnmt3a1, methyl mutation, from PCèVD, using the primers: 
FW 5ʹ-TTGGGGGCAGTGTCGACAATGACCTCTCC-3ʹ 
RV 5ʹ-GGAGAGGTCATTGTCGACACTGCCCCCAA-3ʹ 
 
Dnmt3a1, PWWP mutation, from WPèST, using the primers: 
FW 5ʹ-CAATGCGGCCCGTCGACCAGGAGAAGCCCCGCA-3ʹ 
RV 5ʹ-TGCGGGGCTTCTCCTGGTCGACGGGCCGCATTG-3ʹ 
 
Dnmt3b1, methyl mutation, from PCèGT, using the primers: 
FW 5ʹ-TTGGCGGAAGCGGTACCAACGATCTCTC-3ʹ 
RV 5ʹ-GAGAGATCGTTGGTACCGCTTCCGCCAA-3ʹ 
 
Dnmt3b1, PWWP point mutation, from WPèST, using the primers: 
FW 5ʹ-CCATGGCGGTCGACCAGGAGAAGCCCTTG-3ʹ 
RV 5ʹ-CAAGGGCTTCTCCTGGTCGACCGCCATGG-3ʹ 
 
Inducible shRNAs  
TRIPZ doxycycline inducible vectors were purchased from Dharmacon. TRIPZ 
shRNA was used as a scramble control. shDnmt3b 02 (V3THS_402302) was selected 
as the best shRNA purchased from Dharmacon and was used directly as an shRNA 
against the 3ʹUTR of Dnmt3b. To obtain a Dnmt3a 3ʹUTR shRNA, the following 
sequence was inserted into the TRIPZ vector using EcoRI and XhoI for cutting and 
pasting. 
5ʹTGCTGTTGACAGTGAGCGAGCATCCACTGTGAATGATAAGTAGTGAAGC
CACAGATGTACTTATCATTCACAGTGGATGCCTGCCTACTGCCTCGGA3ʹ 
 
Mutation Infections 
Primary human keratinocytes grown in KSFM medium were infected for two 
consecutives days overnight with doxycycline-inducible shRNAs against DNMT3A 
or DNMT3B 3ʹUTR, or against a random sequence (TRIPZ). On the third day, 
doxycycline was added to the medium at a final concentration of 5 µg/ml, and cells 
were infected for three consecutive days (with a 4 to 5 hr incubation) with a retroviral 
vector expressing GFP and the cDNA of Dnmt3a1 or Dntm3b1 (wild-type or mutant 
isoforms). Double-positive RFP+ and GFP+ cells were maintained in doxycycline and 
puromycin for 2 extra days, trypsinized, and sorted by FACS using a FACS ARIA 
machine (BD Biosciences), prior to transplanting them into immunocompromised 
mice. 
 
Western Immunoblotting 
Proteins were extracted using RIPA buffer (4% SDS, 20% glycerol, 10% 2- 
mercaptoethanol, 0.004% bromophenol blue, and 0.125 Tris-HCl). Protein 
concentrations were quantified using BioRAD® BCA protein assay kit (Bio-Rad, 
23227). Lysates were separated by a 10% SDS-PAGE gel, transferred to a 
nitrocellulose membrane, and incubated with rabbit anti-Dnmt3a (Santa Cruz 1:1000), 
rabbit anti-Dnmt3b (Novus 1:1000), and/or mouse anti-tubulin (Santa Cruz) (used as 
a loading control).  TP63 antibody was purchased from Abcam (Ab53039) and used 
1:1000 for western blot after endogenous immunoprecipitation of Dnmt3a or Dnmt3b.  
  
Luciferase Reporter Assay 
Primary human keratinocytes cultured in 12-well plates in KSFM medium were 
infected 2× for 4 hr with the short hairpin RNA constructs shCTRL, shDNMT3a, or 
shDNMT3b cloned in the pLKO lentiviral vector. After puromycin selection, infected 
cells at 80% confluence were transfected with 500 µl KSFM medium that had been 
pre-incubated with 3 µl of lipofectamine (Thermo Fisher Scientific, 11668027) 
containing 1 µg of the TK-empty or the TK-C38/C40 (p63 enhancer) luciferase 
plasmids, and 100 ng of the Renilla luciferase control plasmid. Incubation medium 
was changed for fresh KSFM after 6 hrs. Luciferase intensity was measured using the 
Dual-Luciferase Reporter Assay (Promega, e1910) according to the manufacturer’s 
protocol.  
 
Gene ontology  
Gene ontology (GO) analyses was done using Genomatix 
(https://www.genomatix.de/), 
using the Gene Ranker package, with a p value of 0.01 and an adjusted p value of 
0.05. 
 
Skin Reconstitution Assay 
For each transplant, 3  × 106 primary human keratinocytes infected with the TRIPZ 
vector expressing RFP and shCtrl, shDntm3a, or shDnmt3b were first mixed with 3 
million keratinocytes infected with a GFP-expressing vector, then mixed with 4 × 106 
newborn (P2) mouse fibroblasts, and transplanted onto the back of Swiss Nude mice 
as previously described (Lichti et al., 2008). shRNA expression was induced by 
administering 2 mg/ml of doxycycline in 5% sucrose drinking water. Skin grafts were 
collected 4 weeks after transplantation, fixed for 2 hr in 4% PFA, and embedded in 
OCT for cryosections. Nuclei were stained with DAPI (1:10000). Pictures of direct 
fluorescence were acquired using a Leica SP5 confocal microscope. 
 
Clonogenic Assay 
Clonogenic assays were performed as previously described (Janich et al., 2013). 
Briefly, EpSCs growing on feeders were infected with precipitated lentiviral particles 
produced by 293T cells transfected with the mentioned plasmids. Puromycin-resistant 
primary keratinocytes were selected and detached from the feeder layer, and 1000 
keratinocytes were seeded again on a new layer of feeder fibroblasts. These were 
cultured for at least 14 days, after which they were fixed for 20 min with 10% 
formalin, washed 2× with PBS, and stained with a mixture of Rhodamil Blue (0.5%) 
and Crystal Violet (0.5%) for 30 min. 
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